Tag: Human Papillomavirus (HPV)
HPV-Associated Cancer Incidence Starting to Increase
Cervical cancer incidence plateaued in highest-income counties, increased in lowest-income counties in recent years
Incidence of Oropharyngeal Cancer Projected to Rise in U.S. Men
Under a status quo scenario based on current levels of HPV vaccination, 792,000 OPC cases in men would be prevented by the year 2100
Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years
HPV Vaccine Will Have Modest Impact on Oropharynx Cancer Incidence by 2045
However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults
Human Papillomavirus Infection Tied to Preterm Birth Risk
Risk increased for both persistent and placental infection and for both spontaneous and all preterm births
Parents Increasingly Cite Safety Concerns in HPV Vaccine Refusal
Despite 79.9 percent increase in parent-reported safety concerns, there was a drop in HPV vaccine-related reported adverse reactions
Cutaneous Beta-HPV May Up Risk for Cutaneous Squamous Cell Carcinoma
Beta-HPV detected in skin swabs may predict cuSCC risk, but no link seen for serologic evidence of past beta-HPV infection
HPV Vaccination Rates Low for Young Adults
Rates low for 18- to 21-year-olds reporting vaccination at any age or initiating in young adulthood
HPV Vaccination Rates Suboptimal Within Ages 9 to 12 Years
For most of the study period, higher rates of HPV vaccination initiation and up-to-date rates were seen for non-Hispanic Blacks, Hispanics
Oral HPV Infection Detected in Infants, Young Children
Persistent, oral, high-risk HPV infection for children linked to oral HPV carriage of mother at birth, seroconversion of mother to high-risk HPV
